

Appl. no. 10/655,905  
Amdt. dated 5/11/04

REMARKS

The last three words of the title were inadvertently omitted at the time the present divisional application was filed. Applicants respectfully request the amendment of the title as noted above so that it is the same as that in the parent patent application number 09/936,603 (now U.S. Patent No. 6,652,855.)

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-0630 (Ref. Docket No. P1747R2D1).

Respectfully submitted,  
GENENTECH, INC.


Date: May 12, 2004

By: Lee K. Tan  
Lee K. Tan, Ph.D.  
Reg. No. 39,447  
Telephone: (650)225-4462

document# 155207



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Garovoy et al.  Serial No.: 10/655,905  Publication No.: US-2004-0047859-A1  Filed: September 5, 2003  Title: TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES OF LFA-1 ANTAGONIST	Group Art Unit:  Examiner: To be assigned  Confirmation No: 7684  Customer No: 09157  <div style="text-align: center;"><small>CERTIFICATE OF MAILING</small> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  May 12, 2004  Jennifer Fisk</div>
---	---

**REQUEST FOR CORRECTION TO PATENT APPLICATION PUBLICATION**

PGPub  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached is page 1 of patent application publication number US-2004-0047859-A1 with the errors marked in red. Please make the corrections as follows:

**Corrections to the Specification:**

Please correct the title to read as follows wherein underlining, 00, indicates added terminology.

TREATMENT OF LFA-1 ASSOCIATED DISORDERS WITH INCREASING DOSES OF LFA-1  
ANTAGONIST

The last three words of the title were inadvertently left off at the time the present divisional application was filed. A preliminary amendment affecting this change is being filled concurrently with this request.

Applicants hereby authorize the Commissioner to charge any fees that the Patent Office determines are due in connection with the filing of this document to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: May 12, 2004

By: 

Lee K. Tan, Ph.D.

Reg. No. 39,447

Telephone No. (650) 225-4462

doc. # 152852



US 20040047859A1

(19) **United States**(12) **Patent Application Publication**  
**Garovoy et al.**(10) **Pub. No.: US 2004/0047859 A1**  
(43) **Pub. Date: Mar. 11, 2004**(54) **TREATMENT OF LFA-1 ASSOCIATED  
DISORDERS WITH INCREASING DOSES***of LFA-1 Antagonist*(75) **Inventors: Marvin R. Garovoy, San Anselmo, CA  
(US); Susan M. Kramer, San  
Francisco, CA (US); Russell L.  
Dedrick, Kensington, CA (US); Karen  
Starko, Hillsborough, CA (US)**

Correspondence Address:

**GENENTECH, INC.****1 DNA WAY****SOUTH SAN FRANCISCO, CA 94080 (US)**(73) **Assignees: Genentech, Inc., South San Francisco,  
CA (US); Xoma Ltd., Berkeley, CA (US)**(21) **Appl. No.: 10/655,905**(22) **Filed: Sep. 5, 2003****Related U.S. Application Data**(62) **Division of application No. 09/936,603, filed on Feb.  
11, 2002, now Pat. No. 6,652,855, filed as 371 of**international application No. PCT/US00/07189, filed  
on Mar. 17, 2000.(60) **Provisional application No. 60/125,351, filed on Mar.  
19, 1999. Provisional application No. 60/125,228,  
filed on Mar. 19, 1999.****Publication Classification**(51) **Int. Cl.<sup>7</sup> ..... A61K 39/395**(52) **U.S. Cl. .... 424/143.1**(57) **ABSTRACT**

A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose.